The addition of bevacizumab to paclitaxel or capecitabine has demonstrated improved progression-free survival ( PFS ) and objective response rate ( ORR ) as compared with chemotherapy alone in patients with HER2-negative locally recurrent or metastatic breast cancer ( LR/MBC ) .